GlassScriptPhysician profile
Deepika Mathialagan
NPI 1730742594
$2,431.33
in general payments reported to CMS, 2019-2025
23 companies · $898 in 2025
The $898 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.04 · 2023: $427 · 2024: $1,044 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.30 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $509.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $333.52 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $317.59 | 2023-2025 | |
| Lilly USA, LLC | $250.33 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $175.08 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $164.07 | 2024-2025 | Veozah |
| Abbvie INC. | $158.12 | 2023-2025 | |
| Exact Sciences Corporation | $122.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.51 | 2024-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.73 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.95 | 2024 | Xifaxan |
| Hologic Sales and Service, LLC | $24.02 | 2025 | Aptima |
| Becton, Dickinson and Company | $22.56 | 2025 | Bd Max System, Bd Max Instrument |
| Vanda Pharmaceuticals INC. | $22.16 | 2022 | |
| Corium, LLC | $21.99 | 2024 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $21.56 | 2023 | Zio Xt Patch |
| Aspira Women'S Health INC | $20.88 | 2022 | |
| Axsome Therapeutics, INC. | $20.29 | 2025 | Auvelity |
| Abbott Laboratories | $19.76 | 2025 | Freestyle Libre 3 |
| Seqirus USA INC | $17.72 | 2024 | Flucelvax, Fluad |
| Amgen INC. | $16.49 | 2025 | Repatha |
| Daiichi Sankyo INC. | $15.76 | 2024 | Injectafer |
| Medtronic, INC. | $14.87 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Mathialagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.